Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS. (Q47194002)

11 January 2018

title

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS. (English)

1 reference

11 January 2018

main subject

saxagliptin hydrate

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

9

1 reference

11 January 2018

Mark Arnold

12

1 reference

11 January 2018

author name string

Xiaohui Sophia Xu

1

1 reference

11 January 2018

Stephen R Dueker

2

1 reference

11 January 2018

Lisa J Christopher

3

1 reference

11 January 2018

Pete N Lohstroh

4

1 reference

11 January 2018

Chi Fung Anther Keung

5

1 reference

11 January 2018

Kai Kevin Cao

6

1 reference

11 January 2018

Samuel J Bonacorsi

7

1 reference

11 January 2018

Laura Cojocaru

8

1 reference

11 January 2018

W Griffith Humphreys

10

1 reference

11 January 2018

Bruce Stouffer

11

1 reference

11 January 2018

publication date

1 August 2012

1 reference

11 January 2018

published in

Bioanalysis

1 reference

11 January 2018

volume

4

1 reference

11 January 2018

issue

15

1 reference

11 January 2018

page(s)

1855-1870

1 reference

11 January 2018

Accelerator mass spectrometry-enabled studies: current status and future prospects

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical (14)C measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

A High-Throughput Method for the Conversion of CO2 Obtained from Biochemical Samples to Graphite in Septa-Sealed Vials for Quantification of 14C via Accelerator Mass Spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Analytical validation of accelerator mass spectrometry for pharmaceutical development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Biological accelerator mass spectrometry at Uppsala University

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.12.171

21 January 2018

Identifiers

DOI

10.4155/BIO.12.171

1 reference

11 January 2018

1 reference

11 January 2018